Updates on COVID-19 Treatment Recommendations

On January 26th, 2023, the FDA announced that Evusheld is no longer authorized for emergency use in the United States. Please visit the FDA’s website and view ASPR’s information sheet for additional details.

Outpatient antiviral treatments for COVID-19, including oral antivirals (OAVs) and IV remdesivir (Veklury), effectively reduce the risk of hospitalization and death. Nirmatrelvir with ritonavir (Paxlovid) is the preferred treatment for most outpatients or remdesivir if Paxlovid is contraindicated. The oral antiviral molnupiravir (Lagevrio) is authorized as an alternative when Paxlovid and remdesivir are not accessible or clinically appropriate. (NIH COVID-19 Treatment Guidelines for Non-Hospitalized Adults) The antivirals Paxlovid, remdesivir, and molnupiravir are expected to be active against circulating subvariants.

Categories: PulsePublished On: January 27th, 2023Tags: , ,

Share

Related Posts